Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer-mediated malignant pleural effusion

Oncology Reports

Volumn 29, Issue 6, 2013, Pages 2332-2340

  Du, Nan ^a   Li, Xiaosong ^a   Li, Fang ^a   Zhao, Hui ^a   Fan, Zhongyi ^a   Ma, Junxun ^a   Fu, Yan ^a   Kang, Huanrong ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Bevacizumab; Intrapleural chemotherapy; Malignant pleural effusion; Non small cell lung cancer

Indexed keywords

BEVACIZUMAB; BLEOMYCIN; CARBOPLATIN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; PACLITAXEL; VASCULOTROPIN;

ADULT; AGED; ARTICLE; BLEEDING; CANCER GRADING; DIARRHEA; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERTENSION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PLEURA EFFUSION; PLEURA FLUID; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHINORRHEA; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; FEMALE; GENE EXPRESSION; HUMANS; LUNG NEOPLASMS; MALE; PLEURAL EFFUSION, MALIGNANT; QUALITY OF LIFE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 84876204266     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2349     Document Type: Article

References (54)

1. Sanz N, Aguado P, de Agustin JC, et al: Parapneumonic effussion. A review of 33 cases over 6 years. Cir Pediatr 18: 77-82, 2005 (In Spanish).
2. Ramalingam S and Belani C: Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist 13 (Suppl 1): 5-13, 2008.
3. Masuno T, Kishimoto S, Ogura T, et al: A comparative trial of LC9018 plus doxorubicin and doxorubicin alone for the treatment of malignant pleural effusion secondary to lung cancer. Cancer 68: 1495-1500, 1991.
4. Rusch VW, Figlin R, Godwin D and Piantadosi S: Intrapleural cisplatin and cytarabine in the management of malignant pleural effusions: a Lung Cancer Study Group trial. J Clin Oncol 9: 313-319, 1991.
5. Luh KT, Yang PC, Kuo SH, Chang DB, Yu CJ and Lee LN: Comparison of OK-432 and mitomycin C pleurodesis for malignant pleural effusion caused by lung cancer. A randomized trial. Cancer 69: 674-679, 1992.
6. Tohda Y, Iwanaga T, Takada M, et al: Intrapleural administration of cisplatin and etoposide to treat malignant pleural effusions in patients with non-small cell lung cancer. Chemotherapy 45: 197-204, 1999. (Pubitemid 29213402)
7. Ishida A, Miyazawa T, Miyazu Y, et al: Intrapleural cisplatin and OK432 therapy for malignant pleural effusion caused by non-small cell lung cancer. Respirology 11: 90-97, 2006.
8. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS and Dvorak HF: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219: 983-985, 1983.
9. Fontanini G, Faviana P, Lucchi M, et al: A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma. Br J Cancer 86: 558-563, 2002. (Pubitemid 34185092)
10. Sack U, Hoffmann M, Zhao XJ, et al: Vascular endothelial growth factor in pleural effusions of different origin. Eur Respir J 25: 600-604, 2005. (Pubitemid 40528750)
11. Kobold S, Hegewisch-Becker S, Oechsle K, Jordan K, Bokemeyer C and Atanackovic D: Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites? Oncologist 14: 1242-1251, 2009.
12. Ferrara N, Gerber HP and LeCouter J: The biology of VEGF and its receptors. Nat Med 9: 669-676, 2003. (Pubitemid 36749215)
13. Pichelmayer O, Zielinski C and Raderer M: Response of a nonmalignant pleural effusion to bevacizumab. N Engl J Med 353: 740-741, 2005. (Pubitemid 41175690)
14. Neragi-Miandoab S: Malignant pleural effusion, current and evolving approaches for its diagnosis and management. Lung Cancer 54: 1-9, 2006.
15. Cohen MH, Gootenberg J, Keegan P and Pazdur R: FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 12: 713-718, 2007. (Pubitemid 47036205)
16. Ribeiro SC, Vargas FS, Antonangelo L, et al: Monoclonal anti-vascular endothelial growth factor antibody reduces fluid volume in an experimental model of inflammatory pleural effusion. Respirology 14: 1188-1193, 2009.
17. Teixeira LR, Vargas FS, Acencio MM, et al : Blockage of vascular endothelial growth factor (VEGF) reduces experimental pleurodesis. Lung Cancer 74: 392-395, 2011.
18. Pichelmayer O, Gruenberger B, Zielinski C and Raderer M: Bevacizumab is active in malignant effusion. Ann Oncol 17: 1853, 2006.
19. Sahn SA: Management of malignant pleural effusions. Monaldi Arch Chest Dis 56: 394-399, 2001.
20. Musani AI: Treatment options for malignant pleural effusion. Curr Opin Pulm Med 15: 380-387, 2009.
21. Los G, Mutsaers PH, van der Vijgh WJ, Baldew GS, de Graaf PW and McVie JG: Direct diffusion of cis-diamminedichloro-platinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res 49: 3380-3384, 1989. (Pubitemid 19162154)
22. Walker-Renard PB, Vaughan LM and Sahn SA: Chemical pleurodesis for malignant pleural effusions. Ann Intern Med 120: 56-64, 1994. (Pubitemid 24011502)
23. Aslam N and Marino CR: Malignant ascites: new concepts in pathophysiology, diagnosis, and management. Arch Intern Med 161: 2733-2737, 2001. (Pubitemid 33134851)
24. Grove CS and Lee YC: Vascular endothelial growth factor: the key mediator in pleural effusion formation. Curr Opin Pulm Med 8: 294-301, 2002. (Pubitemid 34625963)
25. Patane S, Marte F, Di Bella G and Davi M: Pericardial effusion with elevated serum carbohydrate antigen 125 levels and ovarian tumor mass. Int J Cardiol 127: e105-e107, 2008. (Pubitemid 351885068)
26. Yokoyama T, Tanaka A, Kato S and Aizawa H: Multiple myeloma presenting initially with pleural effusion and a unique paraspinal tumor in the thorax. Intern Med 47: 1917-1920, 2008.
27. Chen Y, Liang B, Zhao YJ, Wang SC, Fan YB and Wu GP: Transcription expression and clinical significance of vascular endothelial growth factor mRNA and endostatin mRNA in pleural effusions of patients with lung cancer. Diagn Cytopathol 40: 287-291, 2012.
28. Folkman J, Merler E, Abernathy C and Williams G: Isolation of a tumor factor responsible for angiogenesis. J Exp Med 133: 275-288, 1971.
29. Mohammed KA, Nasreen N, Hardwick J, Logie CS, Patterson CE and Antony VB: Bacterial induction of pleural mesothelial monolayer barrier dysfunction. Am J Physiol Lung Cell Mol Physiol 281: L119-L125, 2001.
30. Folkman J: Tumor angiogenesis and tissue factor. Nat Med 2: 167-168, 1996.
31. Zebrowski BK, Yano S, Liu W, et al: Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin Cancer Res 5: 3364-3368, 1999.
32. Strizzi L, Catalano A, Vianale G, et al: Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 193: 468-475, 2001. (Pubitemid 32266815)
33. Presta LG, Chen H, O'Connor SJ, et al: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57: 4593-4599, 1997. (Pubitemid 27441066)
34. Shaheen RM, Tseng WW, Vellagas R, et al : Effects of an antibody to vascular endothelial growth factor receptor-2 on survival, tumor vascularity, and apoptosis in a murine model of colon carcinomatosis. Int J Oncol 18: 221-226, 2001.
35. Hama M, Komatsu Y and Hachiya T: A case of lung cancer showing marked reduction of pleural effusion by bevacizumab in combination with carboplatin and paclitaxel. Gan To Kagaku Ryoho 38: 1877-1879, 2011 (In Japanese).
36. Numnum TM, Rocconi RP, Whitworth J and Barnes MN: The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. Gynecol Oncol 102: 425-428, 2006. (Pubitemid 44353660)
37. Hamilton CA, Maxwell GL, Chernofsky MR, Bernstein SA, Farley JH and Rose GS: Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer. Gynecol Oncol 111: 530-532, 2008.
38. Kesterson JP, Mhawech-Fauceglia P and Lele S: The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: a case report. Gynecol Oncol 111: 527-529, 2008.
39. Volm M, Koomagi R and Mattern J: Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer. Int J Cancer 74: 64-68, 1997. (Pubitemid 27157857)
40. Kassim SK, El-Salahy EM, Fayed ST, et al: Vascular endothe lial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients. Clin Biochem 37: 363-369, 2004. (Pubitemid 38490454)
41. Kumar H, Heer K, Lee PW, et al: Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer. Clin Cancer Res 4: 1279-1285, 1998. (Pubitemid 28213341)
42. Matsuyama W, Hashiguchi T, Mizoguchi A, et al: Serum levels of vascular endothelial growth factor dependent on the stage progression of lung cancer. Chest 118: 948-951, 2000.
43. Cheng D, Rodriguez RM, Perkett EA, et al: Vascular endothelial growth factor in pleural fluid. Chest 116: 760-765, 1999. (Pubitemid 29428497)
44. Kraft A, Weindel K, Ochs A, et al: Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 85: 178-187, 1999. (Pubitemid 29031373)
45. Thickett DR, Armstrong L and Millar AB: Vascular endothelial growth factor (VEGF) in inflammatory and malignant pleural effusions. Thorax 54: 707-710, 1999. (Pubitemid 29341408)
46. Yanagawa H, Takeuchi E, Suzuki Y, Ohmoto Y, Bando H and Sone S: Vascular endothelial growth factor in malignant pleural effusion associated with lung cancer. Cancer Immunol Immunother 48: 396-400, 1999. (Pubitemid 29461393)
47. Verheul HM, Hoekman K, Jorna AS, Smit EF and Pinedo HM: Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation. Oncologist 5 (Suppl 1): 45-50, 2000. (Pubitemid 30225457)
48. Ishimoto O, Saijo Y, Narumi K, et al: High level of vascular endothelial growth factor in hemorrhagic pleural effusion of cancer. Oncology 63: 70-75, 2002. (Pubitemid 34977940)
49. Kishiro I, Kato S, Fuse D, Yoshida T, Machida S and Kaneko N: Clinical significance of vascular endothelial growth factor in patients with primary lung cancer. Respirology 7: 93-98, 2002. (Pubitemid 34662938)
50. Momi H, Matsuyama W, Inoue K, et al: Vascular endothelial growth factor and proinflammatory cytokines in pleural effusions. Respir Med 96: 817-822, 2002. (Pubitemid 35238107)
51. Harlozinska A, Sedlaczek P, Kulpa J, et al: Vascular endothelial growth factor (VEGF) concentration in sera and tumor effusions from patients with ovarian carcinoma. Anticancer Res 24: 1149-1157, 2004. (Pubitemid 38624955)
52. Rudlowski C, Pickart AK, Fuhljahn C, et al: Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long-term follow-up. Int J Gynecol Cancer 16 (Suppl 1): 183-189, 2006.
53. Watanabe M, Boyer JL and Crystal RG: AAVrh.10-mediated genetic delivery of bevacizumab to the pleura to provide local anti-VEGF to suppress growth of metastatic lung tumors. Gene Ther 17: 1042-1051, 2010.
54. Konner JA, Grabon DM, Gerst SR, et al: Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer. J Clin Oncol 29: 4662-4668, 2011.